Eclipse Treatment Planning System
FDA Clearance Information
The Eclipse Treatment Planning System was cleared by the FDA via the 510(k) pathway on August 15, 2017. It is manufactured by Varian Medical Systems and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Radiation therapy treatment planning
- Calculation and evaluation of radiation dose distributions
- Use in clinical radiotherapy planning for cancer treatment
Clinical Applications
- Planning external-beam radiation therapy treatments
- Calculating radiation dose distributions for treatment plans
- Evaluating dose to the target and surrounding organs at risk
- Planning complex radiation treatments, including intensity-modulated radiation therapy and volumetric modulated arc therapy, when supported by the cleared system configuration
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- This is software rather than an implanted or disposable device, so it does not have a physical size, catheter diameter, or vessel-compatibility requirement.
- Treatment plans require patient imaging, accurate anatomy definition, treatment-machine data, and review by qualified radiation oncology professionals.
- The system must be configured and validated for the radiation-delivery equipment, treatment technique, dose-calculation algorithm, and clinical workflow in use.
- MRI images may be used for treatment planning only when they are acquired, registered, and quality-checked according to the institution's approved workflow; the software itself is not an MRI-safe implant or device.
- Independent plan checks, quality assurance, and clinician approval are required before radiation is delivered.
Frequently Asked Questions
What are the clinical indications for Eclipse Treatment Planning System?
The Eclipse system is indicated for use in planning radiotherapy treatments, particularly in cancer cases requiring precise dose calculations.
What outcomes have been reported in clinical studies?
Studies report accurate dose calculations and effective dose delivery to target volumes, with comparisons showing performance on par with other systems.
What complications have been reported?
Safety data indicate potential calculation discrepancies due to measurement parameter variations, but no significant adverse events have been reported.